$LEG

Leggett & Platt Reports 2Q 2026 Results

Leggett & Platt (NYSE: LEG) reported 2Q 2026 sales of $1.0 billion, down 6% year over year, with 2Q EPS of $0.33 and adjusted EPS of $0.39. Adjusted EBIT rose to $89 million. The company cited weak bedding and consumer demand and said HSR waiting expired for its planned merger with Somnigroup (NYSE: SGI), pending shareholder and regulatory approvals.

Original reporting
Published Aug 6, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leggett & Platt Reports 2Q 2026 Results — source image
Decision brief

The 30-second read

$LEGNeutralMed
01

Why it matters

The quarter shows weaker sales and volume, but adjusted EBIT and adjusted EPS improved, supported by metal margin expansion, restructuring benefits, and favorable items expected not to repeat. The next decision point is shareholder approval at a special meeting planned for Aug. 20, after the HSR waiting period expired in June.

02

Market read

Traders get a fresh earnings datapoint (sales, EPS, margins) plus a concrete M&A milestone schedule into Aug. 20, which can drive risk premium and positioning.

03

What to watch

The merger is still pending with remaining regulatory approvals; any delay or condition change could dominate valuation more than the quarter’s operating details.

Relevance 8/10Novelty 6/10Timing: 2Q results released pre-market today, with Aug. 20 merger vote as the next catalyst.

Background

Leggett & Platt is a diversified manufacturer with a planned merger with Somnigroup; it withdrew 2026 guidance while the transaction is pending.

Company-level read

Ticker impact

$LEGNeutralMedium confidence
Context

Leggett & Platt reported 2Q 2026 sales of $1.0B (-6% YoY) and EPS of $0.33, plus updated merger-close timing toward an Aug. 20 shareholder vote.

Expected impact

Near-term trading likely hinges on how investors weigh adjusted EPS strength versus weaker top-line/volume and the merger-close timeline.

Evidence & confidence

The article provides concrete 2Q financials (sales, EPS, EBIT/adjusted EBIT, margins) and a specific pending M&A milestone (HSR waiting period expired in June, shareholder meeting planned Aug. 20, remaining regulatory approvals).

Market effects

Bedding and home-furnishings demand appears pressured by consumer softness and housing-linked weakness, with some offset from bedding components and metal margin expansion.

US demand weakness is emphasized (U.S. mattress units down low double digits), with Europe and other regions described as soft in housing/consumer-linked markets.

Automotive demand is described as mixed by region (Asia underperformance offset by Europe and North America), which can influence sentiment for industrial component suppliers.

Counterpoint

Adjusted EPS improved, but the company flags several favorable items as non-recurring, so the earnings quality may not persist into later quarters.

Key entities

  • Leggett & Platt

    Reported 2Q 2026 results and reiterated expected merger close conditions, including Aug. 20 shareholder approval.

  • Somnigroup International Inc.

    Acquirer in the announced transaction; the article references the pending close timeline and conditions.

  • HSR Antitrust Improvements Act

    HSR waiting period expired in June, removing one procedural hurdle for the merger.

Related articles

$LEGMed

LEGGETT & PLATT INC (LEG): Results of Operations and Financial Condition

LEGGETT & PLATT INC (LEG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d121836dex991.htm PRESS RELEASE DATED AUGUST 6, 2026 PRESS RELEASE DATED AUGUST 6, 2026 EXHIBIT 99.1 FOR IMMEDIATE RELEASE: August 6, 2026 Leggett & Platt Reports 2Q 2026 Results Carthage, MO, August 6, 2026 — • 2Q sales of $1.0 billion, a 6% decrease vs 2Q25, including

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.